사카로마이세스 보울라디 관련 항생제 관련 설사(AAD)

Q: Does 사카로마이세스 보울라디 help with 항생제 관련 설사(AAD)?

Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that 사카로마이세스 보울라디 may support 항생제 관련 설사(AAD) management. Our evidence grade is A (Strong Evidence).

Q: How much 사카로마이세스 보울라디 should I take for 항생제 관련 설사(AAD)?

Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of 사카로마이세스 보울라디?

Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for 사카로마이세스 보울라디 and 항생제 관련 설사(AAD)?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

A 근거 여러 대규모 임상 시험이 일관되게 유의미한 효과를 보여줍니다.

여러 메타분석에서 사카로마이세스 보울라디가 항생제 관련 설사(AAD) 위험을 47~53% 감소시키는 것으로 나타났습니다(RR 0.47). AAD 예방에 대해 가장 많이 연구된 프로바이오틱이며 항생제 종류에 관계없이 일관되게 긍정적인 결과를 보입니다.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

결론

Key Study Findings

Observational Study n=279

Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …

Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs 효과: L. rhamnosus GG used by 91.8% None

대상 집단: Italian primary care pediatricians

Review

The evidence for probiotics in the treatment of digestive disorders in the pediatric population.

Dose: None vs: None Outcome: None 효과: None None

대상 집단: Pediatric population

Review

Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …

Dose: None vs: None Outcome: None 효과: None None

대상 집단: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children

Other

Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …

Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI 효과: None None

대상 집단: Pediatric patients with GI disorders

Review

Clostridioides difficile Infections: Prevention and Treatment Strategies.

Dose: None vs: None Outcome: C. difficile infection treatment outcomes 효과: None None

대상 집단: Patients with C. difficile infection

Randomized Controlled Trial n=47 1 weeks

[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants …

Dose: None vs: Control Outcome: Gut microbiota composition 효과: None P<0.017

대상 집단: Children

Key Statistics

연구

5000

참여자

↑

Positive

등급

Referenced Papers

Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. Review

Probiotics and antimicrobial … 2025 26 인용

The evidence for probiotics in the treatment of digestive disorders in the pediatric population. Review

Journal of gastroenterology … 2025 10 인용

Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. Other

Antibiotics (Basel, Switzerland) 2025

Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. Other

Boletin medico del … 2025

High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A … Other

Open forum infectious … 2024 7 인용

[A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. RCT

Zhongguo dang dai … 2024 5 인용

Clostridioides difficile Infections: Prevention and Treatment Strategies. Review

Advances in experimental … 2024 2 인용

Current understanding of antibiotic-associated dysbiosis and approaches for its management. Review

Therapeutic advances in … 2023 97 인용

Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. Systematic Review

Frontiers in pharmacology 2023 20 인용

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. Review

Cureus 2023 19 인용

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. Review

Cureus 2023 5 인용

The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview. Review

The Journal of … 2023 1 인용

Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. Review

Archivos argentinos de … 2022 23 인용

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. Review

World journal of … 2019 92 인용

Clostridium difficile Colitis Prevention and Treatment. Review

Advances in experimental … 2019 17 인용

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Other

Frontiers in medicine 2018 450 인용

Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. Systematic Review

PloS one 2018 205 인용

Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Review

Pharmacological research 2018 132 인용

Chinese clinical practice guidelines for acute infectious diarrhea in children. Review

World journal of … 2018 52 인용

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Review

The American journal … 2018 46 인용

Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. Review

World journal of … 2017 68 인용

Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Meta-Analysis

Journal of pediatric … 2016 233 인용

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Review

Clinical and experimental … 2016 82 인용

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Other

Open forum infectious … 2016 58 인용

Probiotic Bacterial and Fungal Strains: Claims with Evidence. Review

Digestive diseases (Basel, … 2016 37 인용

Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Meta-Analysis

The Cochrane database … 2015 233 인용

Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Review

Antibiotics (Basel, Switzerland) 2015 104 인용

Probiotics for Prevention and Treatment of Diarrhea. Review

Journal of clinical … 2015 35 인용

Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. Review

Nutrition in clinical … 2015 31 인용

[Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. Review

Nutricion hospitalaria 2015 5 인용

Saccharomyces boulardii CNCM I-745 in different clinical conditions. Review

Expert opinion on … 2014 57 인용

[Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. Other

MMW Fortschritte der … 2014 14 인용

[Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. Review

MMW Fortschritte der … 2014 3 인용

Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. RCT

The American journal … 2012 104 인용

Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. Other

The American journal … 2012 5 인용

[Effectiveness and safety of probiotics in children on the basis of clinical trials]. Review

Medycyna wieku rozwojowego 2012 1 인용

Probiotics for prevention and treatment of diarrhea. Review

Journal of clinical … 2011 432 인용

Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. Meta-Analysis

World journal of … 2010 512 인용

Probiotics: preventing antibiotic-associated diarrhea. Other

Journal for specialists … 2010 22 인용

Probiotics. Review

American journal of … 2010

Saccharomyces boulardii in childhood. Review

European journal of … 2009 91 인용

Probiotics as prevention and treatment for diarrhea. Review

Current opinion in … 2009 82 인용

Probiotics, prebiotics, and synbiotics. Review

Advances in biochemical … 2008 535 인용

Probiotics for prevention of antibiotic-associated diarrhea. Review

Journal of clinical … 2008

Probiotics. Review

American family physician 2008

Probiotics and prebiotics: effects on diarrhea. Review

The Journal of … 2007 265 인용

Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Systematic Review

The Cochrane database … 2007

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Meta-Analysis

The American journal … 2006 918 인용

Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. Meta-Analysis

CMAJ : Canadian … 2006 197 인용

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. Review

Journal of clinical … 2006 112 인용

Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. RCT

Medical science monitor … 2006

Protection from gastrointestinal diseases with the use of probiotics. Review

The American journal … 2001 648 인용

Treatment and prevention of antibiotic associated diarrhea. Review

International journal of … 2000 181 인용

Mechanisms and management of antibiotic-associated diarrhea. Review

Clinical infectious diseases … 1998 346 인용

Pharmaceutical probiotics for the treatment of anaerobic and other infections. Other

Anaerobe 1997 40 인용

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. CCT

Gastroenterology 1989 418 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:: 250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:: 500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:: 500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:: 250-500 mg/day starting 5 days before travel

상한량: Well-tolerated up to 1,000 mg/day in clinical trials

연구에서 사용된 용량

용량	기간	효과	N
None	--	Mixed	279
None	--	Mixed	--
None	--	Positive	--
None	--	Positive	--
None	--	Positive	--
None	1 weeks	Positive	47
None	20 weeks	Positive	564
None	--	Positive	--

권장 복용 시간: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

보고된 부작용

⚠ Mild gas and bloating
⚠ Rare: fungemia in critically ill patients with central venous catheters
⚠ Thirst (yeast may increase water requirements)
⚠ Very rare: potential environmental contamination risk in ICU settings

알려진 상호작용

● Antifungal medications (may kill S. boulardii, reducing effectiveness)
● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

일일 최대 섭취 허용량: Well-tolerated up to 1,000 mg/day in clinical trials

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 사카로마이세스 보울라디 help with 항생제 관련 설사(AAD)?

Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that 사카로마이세스 보울라디 may support 항생제 관련 설사(AAD) management. Our evidence grade is A (Strong Evidence).

How much 사카로마이세스 보울라디 should I take for 항생제 관련 설사(AAD)?

Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of 사카로마이세스 보울라디?

Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for 사카로마이세스 보울라디 and 항생제 관련 설사(AAD)?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.

사카로마이세스 보울라디 다른 건강 상태에 대한 근거

클로스트리디오이데스 디피실 감염(CDI) B 여행자 설사 B

한눈에 보기

Evidence Strength92%

High confidence

연구 분석

RCT (3)Meta (5)Other (17)

대안 비교

이 건강 상태에 대한 다른 성분의 비교 결과를 확인하세요.

모든 성분 보기: 항생제 관련 설사(AAD)

자세히 알아보기

References

[1] Ailim Margarita Carías Domínguez et al.. Probiotics Antimicrob Proteins. 2025. Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review. doi:10.1007/s12602-024-10353-w PubMed
[2] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
[3] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
[4] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
[5] Vladimir Hodzhev et al.. Open Forum Infect Dis. 2024. High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent Antibiotic-associated Diarrhea in Adults: A … doi:10.1093/ofid/ofae615 PubMed
[6] Su-Wei Zhang et al.. Zhongguo Dang Dai Er Ke Za Zhi. 2024. [A prospective randomized controlled study on probiotics for the prevention of antibiotic-associated diarrhea in infants and young children]. doi:10.7499/j.issn.1008-8830.2401129 PubMed
[7] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
[8] Dhanasekhar Kesavelu et al.. Ther Adv Infect Dis. 2023. Current understanding of antibiotic-associated dysbiosis and approaches for its management. doi:10.1177/20499361231154443 PubMed
[9] Qingrui Yang et al.. Front Pharmacol. 2023. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. doi:10.3389/fphar.2023.1153070 PubMed
[10] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
[11] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
[12] Amarender S Puri. J Assoc Physicians India. 2023. The Role of Yeast Probiotics in Gastrointestinal Conditions: An Overview. doi:10.5005/japi-11001-0235 PubMed
[13] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
[14] Dorota Czerucka et al.. World J Gastroenterol. 2019. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. doi:10.3748/wjg.v25.i18.2188 PubMed
[15] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
[16] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
[17] Jason C Sniffen et al.. PLoS One. 2018. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. doi:10.1371/journal.pone.0209205 PubMed
[18] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
[19] Jie Chen et al.. World J Pediatr. 2018. Chinese clinical practice guidelines for acute infectious diarrhea in children. doi:10.1007/s12519-018-0190-2 PubMed
[20] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
[21] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
[22] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
[23] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
[24] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
[25] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
[26] Joshua Z Goldenberg et al.. Cochrane Database Syst Rev. 2015. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub4 PubMed
[27] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
[28] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
[29] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
[30] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
[31] Ener Cagri Dinleyici et al.. Expert Opin Biol Ther. 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. doi:10.1517/14712598.2014.937419 PubMed
[32] George Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
[33] G Micklefield. MMW Fortschr Med. 2014. [Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea]. PubMed
[34] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
[35] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
[36] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
[37] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
[38] Lynne V McFarland. World J Gastroenterol. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. doi:10.3748/wjg.v16.i18.2202 PubMed
[39] Kathleen Jones. J Spec Pediatr Nurs. 2010. Probiotics: preventing antibiotic-associated diarrhea. doi:10.1111/j.1744-6155.2010.00231.x PubMed
[40] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
[41] Yvan Vandenplas et al.. Eur J Pediatr. 2009. Saccharomyces boulardii in childhood. doi:10.1007/s00431-008-0879-7 PubMed
[42] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
[43] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
[44] Shira Idit Doron et al.. J Clin Gastroenterol. 2008. Probiotics for prevention of antibiotic-associated diarrhea. doi:10.1097/MCG.0b013e3181618ab7 PubMed
[45] Benjamin Kligler et al.. Am Fam Physician. 2008. Probiotics. PubMed
[46] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
[47] B C Johnston et al.. Cochrane Database Syst Rev. 2007. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. doi:10.1002/14651858.CD004827.pub2 PubMed
[48] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
[49] Bradley C Johnston et al.. CMAJ. 2006. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. doi:10.1503/cmaj.051603 PubMed
[50] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
[51] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
[52] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
[53] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
[54] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
[55] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
[56] C M Surawicz et al.. Gastroenterology. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. doi:10.1016/0016-5085(89)91613-2 PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.

사카로마이세스 보울라디 관련 항생제 관련 설사(AAD)

Embed This Widget

결론

Key Study Findings

Key Statistics

Referenced Papers

Dosage & Usage

일반적으로 사용되는 용량

연구에서 사용된 용량

Safety & Side Effects

보고된 부작용

알려진 상호작용

Frequently Asked Questions

Related Evidence

관련 다른 성분: 항생제 관련 설사(AAD)

사카로마이세스 보울라디 다른 건강 상태에 대한 근거

References